Seasoned Financial Executive Joins OncoCyte as Chief Financial Officer
November 15 2017 - 4:10PM
OncoCyte Corporation (NYSE American:OCX), a
developer of novel, non-invasive tests for the early detection of
cancer, today announced that Mitch Levine has been appointed Chief
Financial Officer, effective November 15, 2017. With 33 years of
experience in the financial industry and extensive expertise in
fundraising for early stage companies Mr. Levine will be
responsible for OncoCyte's finance and financial reporting
activities.
“Mitch is an experienced professional with a
successful healthcare track record and I am confident he will be a
great addition to our senior leadership team,” said Mr.
Annett. “His addition demonstrates our commitment to
strengthening our management team to execute a long term growth
strategy based on the development and commercialization of novel,
liquid biopsy cancer diagnostic tests, including DetermaVu™ for the
early diagnosis of lung cancer.”
Prior to joining OncoCyte, Mr. Levine was the
Managing Partner of Kirby Cove Capital Advisors, which provides
consulting services to international life sciences investment funds
regarding collaboration and investment in US-based life sciences
companies. In 2002, Mr. Levine founded Enable Capital
Management and grew the firm into one of the largest and most
respected brands globally in alternative finance. Its flagship
fund, Enable Growth Partners, provided growth capital to more than
500 private and publicly traded companies, catalyzing
transformative corporate innovation, job growth, and economic
expansion in technology, life sciences, consumer products, and
energy. Prior to founding Enable, Mr. Levine was a founding
member of The Shemano Group, a leading San Francisco-based
investment bank that focused on the capital needs of growth
companies. He has also worked at Bear Stearns and Lehman Brothers.
Mr. Levine received his BA from the University of California,
Davis.
“OncoCyte has the potential to change the
paradigm in the diagnosis and management of lung cancer,” commented
Mr. Levine. “I look forward to working with Bill and the entire
team to ensure that the Company has the resources necessary to
effectively execute its ambitious long term business plan.”
About OncoCyte Corporation
OncoCyte is focused on the development and
commercialization of novel, non-invasive blood and urine (“liquid
biopsy”) diagnostic tests for the early detection of cancer to
improve health outcomes through earlier diagnoses, to reduce the
cost of care through the avoidance of more costly diagnostic
procedures, including invasive biopsy and cystoscopic procedures,
and to improve the quality of life for cancer patients. While
current biopsy tests use invasive surgical procedures to provide
tissue samples in order to determine if a tumor is benign or
malignant, OncoCyte is developing a next generation of diagnostic
tests that will be based on liquid biopsies using blood or urine
samples. OncoCyte’s pipeline products are intended to be
confirmatory diagnostics for detecting lung, breast and bladder
cancer. OncoCyte’s diagnostic tests are being developed using
proprietary sets of genetic and protein markers that differentially
express in specific types of cancer.
DetermaVu™ is a trademark of OncoCyte
Corporation.
Forward Looking Statements
Any statements that are not historical fact
(including, but not limited to statements that contain words such
as “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates” and similar expressions) are forward-looking
statements. These statements include those pertaining to the
implementation and results of research, development, clinical
trials and studies, commercialization plans, future financial
and/or operating results, and future opportunities for OncoCyte,
along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management. Forward-looking
statements involve risks and uncertainties, including, without
limitation, risks inherent in the development and/or
commercialization of potential diagnostic tests or products,
uncertainty in the results of clinical trials or regulatory
approvals, the capacity of our third-party supplied blood sample
analytic system to provide consistent and precise analytic results
on a commercial scale, the need and ability to obtain future
capital, and maintenance of intellectual property rights, and the
need to obtain third party reimbursement for patients’ use of any
diagnostic tests we commercialize. Actual results may differ
materially from the results anticipated in these forward-looking
statements and accordingly as such statements should be evaluated
together with the many uncertainties that affect the business of
OncoCyte, particularly those mentioned in the “Risk Factors” and
other cautionary statements found in OncoCyte’s Securities and
Exchange Commission filings. OncoCyte disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.
Investor Contacts
EVC Group, Inc.Matt Haines / Michael
Polyviou917-733-9297 / 212-850-5600mhaines@evcgroup.com /
mpolyviou@evcgroup.com
Financial Media Contact
GIBSON Communications, LLCTom
Gibson201-476-0322tom@tomgibsoncommunications.com